The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Britain's Serious Fraud Office re-examines funding model

Tue, 24th May 2016 17:13

By Kirstin Ridley

LONDON, May 24 (Reuters) - The Serious Fraud Office (SFO),Britain's leading fraud and corruption investigator andprosecutor, said on Tuesday it was re-examining a funding modelthat has been criticised for risking weakening investigationsand delaying cases.

So-called "blockbuster funding", under which the agency canrequest extra cash for costly cases directly from thegovernment, was criticised in a report published on Tuesday bythe Crown Prosecution Service Inspectorate (CPSI), which reviewsthe effectiveness of the SFO's structures and governance.

The CPSI said such a model, which allows the SFO to shore upits staffing levels with external experts for big cases, coulddamage investigations, did not provide value for money andprevented the agency from building future expertise in-house.

It said that when it inspected the agency 21 percent ofstaff were not permanent employees.

"There is therefore an inherent lack of consistency in (SFO)teams, which becomes particularly problematic because of thelengthy nature of SFO investigations," the report said. "Thisdisruption increases the risk of delay in cases and may weakenthe investigative strategy going forward."

The CPSI report, which praised the SFO board for improvingthe reputation of the agency externally over the last fouryears, also suggested other reforms such as a smaller managementboard, appointing a chief executive, clearer reporting anddelegation lines for committees and holistic risk management.

SFO head David Green said in an emailed statement that theagency was "giving new consideration" to a funding model he hassaid in the past is not perfect, but which "does the job".

He said the SFO was also carefully considering recommendations such as appointing a CEO or chief operatingofficer and changing the structure of the management board.

Legal experts have already criticised a funding model theyargue could lead to political interference with cases that canconcern influential blue-chip British companies. The SFO'scurrent caseload includes investigations into Barclays,Rolls-Royce and GSK.

The SFO operates on a core annual budget of around 35million pounds ($51 mln), although extra cash injections to payfor costly cases have pushed that up to around 50 million poundsa year over the last few years.

Its biggest and costliest cases have included theinvestigation into the alleged manipulation of financialbenchmarks such as Libor (London interbank offered rate), whichto date has yielded one conviction and one guilty plea.

Five former Barclays traders are on trial at Southwark CrownCourt and further trials of individuals accused of manipulatingEuribor (euro interbank offered rate) are expected to begin nextyear. ($1 = 0.6838 pounds) (Reporting by Kirstin Ridley; Editing by Susan Fenton)

More News
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 17:10

Miners, personal goods stocks drag FTSE 100 to two-week low

Burberry slips on rating downgrade

*

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 12:10

LONDON MARKET MIDDAY: Stocks down before Fed minutes and US PMI data

(Alliance News) - Stock prices in London were down at midday on Wednesday, in cautious trade ahead of key US data and central bank minutes in the afternoon.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
29 Dec 2023 13:01

LONDON MARKET CLOSE: UK equities outclassed by other markets in 2023

(Alliance News) - Stock prices in London closed mixed on Friday, the final trading day of 2023, as the annual returns from UK equities were outshone by international markets.

Read more
20 Dec 2023 13:29

GSK buys rights to Hansoh Pharma antibody-drug conjugate

(Sharecast News) - GSK has agreed to buy the rights to an antibody-drug conjugate (ADC) - HS-20093 - from Chinese biopharmaceutical group Hansoh Pharma.

Read more
19 Dec 2023 15:36

German court quashes CureVac patent after challenge by BioNTech

CureVac shares drop 40%Dispute over intellectual property with BioNTech to continue

*

Read more
18 Dec 2023 17:21

Energy stocks lift UK's FTSE 100, Vodafone shines

Vodafone jumps as Iliad offers to merge Italian units

*

Read more
18 Dec 2023 10:07

GSK's dostarlimab trial in endometrial cancer meets primary endpoint

(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.

Read more
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.